Activity of ceftazidime against Gram-negative bacilli from paediatric patients.
Clinically relevant bacterial isolates from paediatric patients were tested for in-vitro susceptibility to ceftazidime. They included 54 strains of coliform bacilli from infants with meningitis, 41 strains of coliforms which were multiply-resistant to aminoglycosides, 65 strains of Pseudomonas aeruginosa from burn unit patients, cystic fibrosis patients and other clinical specimens, and 16 miscellaneous nonfermentative bacilli. The range of MICs for coliform bacilli was from < or = 0.06 to 0.5 mg/l and the MIC90 was 0.25 mg/l. One pseudomonas isolate and two non-fermenters were resistant, but the others were susceptible with an MIC90 of 8 mg/l and a median MIC of 2 mg/l. Ceftazidime has comparable activity to moxalactam, ceftriaxone and cefotaxime against coliform bacilli and greater activity against pseudomonas strains.
The University of Texas Health Science Center at Dallas, Dallas, Texas, USA.
J D
JD
Nelson
S
S
Shelton
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology*; D002648:Child; D003470:Culture Media; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology*; D006801:Humans; D007223:Infant; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects
D000900:Anti-Bacterial Agents; D003470:Culture Media; D002442:Ceftazidime